

Special Issue

Application of Nanomedicine in Metabolic and Chronic Diseases

Message from the Guest Editor

Metabolic and chronic diseases pose a significant global health burden, necessitating innovative therapeutic strategies. In recent years, the application of nanotechnology in the field of medicine has emerged as a promising approach for addressing the challenges associated with metabolic and chronic diseases. Nanomedicine offers a unique opportunity to target specific molecular pathways, improve drug delivery, and enhance therapeutic outcomes. This Special Issue aims to explore the latest advancements in nanomedicine for treating and managing metabolic and chronic diseases. It will cover topics such as nanoscale drug delivery systems and nanotheranostics, focusing on their application in treating metabolic disorders, such as diabetes, and chronic conditions like cardiovascular diseases. It will span from the design and development of nanomedicine formulations to preclinical and clinical evaluations. This Special Issue invites researchers and clinicians to contribute their latest findings, including original research articles and reviews, fostering a comprehensive understanding of nanomedicine's role in revolutionizing chronic disease management.

Guest Editor

Dr. Mehrnaz Abbasi

Department of Nutritional Sciences, College of Human Sciences,
Auburn University, Auburn, AL 36849, USA

Deadline for manuscript submissions

20 August 2025



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/209558

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).